Free
Meeting Abstracts  |   June 2007
Cholinergic Modulation of Sevoflurane Potency in Cortical and Spinal Networks In Vitro 
Author Affiliations & Notes
  • Christian Grasshoff, M.D.
    *
  • Berthold Drexler, M.D.
    *
  • Harald Hentschke, Ph.D.
  • Horst Thiermann, M.D.
  • Bernd Antkowiak, Ph.D.
    §
  • * Research Assistant, † Assistant Professor, § Professor of Experimental Anesthesiology, Experimental Anesthesiology Section, Department of Anesthesiology, University of Tuebingen, Tuebingen, Germany. ‡ Postdoctoral University Lecturer of Pharmacology and Toxicology, GAF Institute of Pharmacology and Toxicology, Munich, Germany.
Article Information
Meeting Abstracts   |   June 2007
Cholinergic Modulation of Sevoflurane Potency in Cortical and Spinal Networks In Vitro 
Anesthesiology 6 2007, Vol.106, 1147-1155. doi:10.1097/01.anes.0000267598.65120.f2
Anesthesiology 6 2007, Vol.106, 1147-1155. doi:10.1097/01.anes.0000267598.65120.f2
MANY potent insecticides and nerve agents belong to the family of organophosphorus compounds. These highly toxic chemicals act by blocking acetylcholinesterase activity, thereby causing a potentially life-threatening cholinergic crisis hallmarked by centrally mediated symptoms such as generalized convulsions, respiratory failure, and cardiovascular instability.1–3 Furthermore, peripheral symptoms including rhinorrhea, hypersalivation, bronchoconstriction, and neuromuscular block are commonly observed.1,4,5 Suicidal and accidental poisoning by organophosphates is a widespread problem in the developing world, causing several hundred thousand casualties every year.6 Scenarios of mass injury such as the terrorist attack in Tokyo in 1995 with the nerve agent sarin occur rarely. However, when they become reality, victims are likely to suffer not only from intoxication but also from physical trauma.1,7 These subjects may have to undergo surgical interventions, raising the need for general anesthesia.8 
So far, little is known about how general anesthetics act in patients afflicted with cholinergic crisis. This problem is of relevance because there is clear evidence in the literature that γ-aminobutyric acid type A (GABAA) receptor–mediated inhibition, a molecular mechanism that is involved in mediating the sedative and hypnotic actions of most clinically used anesthetics, is hampered by cholinergic stimulation: In rat cerebral cortical slices, it was demonstrated that acetylcholine reduces γ-aminobutyric acid (GABA) release from presynaptic terminals by activating muscarinic receptors.9 Furthermore, a recent study has shown that GABA release is also decreased via  nicotinic receptors.10 Besides these presynaptic actions of acetylcholine, further mechanisms may come into play, rendering GABAAreceptor–mediated inhibition ineffective. Excessive neuronal activity, as observed during cholinergic crisis, shifts the equilibrium potential for chloride ions toward more positive values, thereby reducing the amplitude of GABAAreceptor–mediated synaptic events.11,12 In addition, extracellular accumulation of GABA may desensitize synaptically located GABAAreceptors and, as a consequence, depress synaptic GABAergic transmission.
We have previously shown that volatile anesthetics such as halothane, isoflurane, and enflurane depress neuronal activity in cortical networks in vivo  and in vitro  by potentiating GABAAreceptor–mediated synaptic inhibition at concentrations causing sedation and hypnosis.13,14 Assuming that actions on the molecular and network level are linked causally, how does a cholinergic-induced suppression of GABAAreceptor function affect the potency of general anesthetics in depressing neuronal activity? In the current study, interactions between acetylcholine and sevoflurane were analyzed because volatile anesthetics were recommended for maintenance of anesthesia in nerve agent–intoxicated patients.1 Experiments were conducted in organotypic slice cultures derived from the neocortex and spinal cord because these neuronal microcircuits are important substrates for producing major components of general anesthesia such as amnesia, hypnosis, and immobility.14–20 The results indicate that cholinergic stimulation reverses the depressant effects of sevoflurane by different mechanisms in cortical compared with spinal networks (1) by increasing neuronal excitability in both brain regions and (2) by decreasing anesthetic potency in cortical networks.
Materials and Methods
Spinal Slice Cultures
All procedures were approved by the animal care committee (Eberhard-Karls-University, Tuebingen, Germany) and were in accord with the German law on animal experimentation. Spinal cord slices were prepared from embryos of pregnant 129/SvJ mice (days 14 and 15) according to the method described by Braschler et al  .21 Neocortical slices were obtained from 2- to 5-day-old 129/SvJ mice as previously reported.22,23 
Excised slices were placed on a coverslip and embedded in a plasma clot (Sigma, Taufkirchen, Germany). The coverslips were transferred into plastic tubes containing 0.75 ml of nutrient fluid and incubated with 95% oxygen and 5% carbon dioxide at 36.0°C for 1–2 h. One hundred milliliters of nutrient fluid consisted of 25 ml horse serum (Invitrogen, Karlsruhe, Germany), 25 ml Hanks’ Balanced Salt Solution (Sigma), and 50 ml Basal Medium Eagle (Sigma). For spinal slices, nutrient fluid included 10 nm Neuronal Growth Factor (Sigma). The roller tube technique was used to culture the tissue.24 After 1 day in culture, antimitotics (10 μm 5-fluoro-2-deoxyuridine, 10 μm cytosine-b-d-arabino-furanoside, 10 μm uridine [all from Sigma]) were added to reduce proliferation of glial cells. Slices were used after 21 days in vitro  for extracellular recordings.
Extracellular Recordings
Spontaneous action potential activity was recorded as reported previously.13,25,26 In spinal slices, extracellular recordings were performed from visually identified interneurons located in the ventral horn area.27–29 In brief, slices were perfused with artificial cerebrospinal fluid consisting of 120 mm NaCl, 3.3 mm KCl, 1.13 mm NaH2PO4, 26 mm NaHCO3, 1.8 mm CaCl2, and 11 mm D-glucose. The artificial cerebrospinal fluid was bubbled with 95% oxygen and 5% carbon dioxide. Glass electrodes with a resistance of approximately 2–5 MΩ were filled with artificial cerebrospinal fluid and were introduced into the tissue until extracellular spikes exceeding 100 μV in amplitude were visible and single-unit or multiunit activity could be clearly identified. The noise (peak-to-peak) amplitude was usually approximately 50 μV. All experiments were performed at 34°–36°C.
Preparation and Application of Test Solutions
Test solutions containing sevoflurane were obtained by dissolving the liquid form of the anesthetic in artificial cerebrospinal fluid, which was equilibrated with 95% oxygen and 5% carbon dioxide. A closed, air-free system was used to prevent evaporation. Anesthetic levels are given as multiples of minimum alveolar concentration (MAC) of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects. We used the EC50values for general anesthesia proposed by Franks and Lieb.30 Therefore, we assumed that 1 MAC corresponds to an aqueous concentration of 0.35 mm sevoflurane.26 
Sevoflurane was administered via  bath perfusion using gastight syringe pumps (ZAK Medicine Technique, Marktheidenfeld, Germany), which were connected to the experimental chamber via  Teflon tubing (Lee, Frankfurt, Germany). The flow rate was approximately 1 ml/min. To ensure steady state conditions, recordings during anesthetic treatment were conducted 10–15 min after starting the perfusate change. The calibration of the recording system was performed as previously reported.31 
Data Analysis
Data were bandpass filtered between 3 and 10 kHz as acquired on a personal computer using the Digidata 1200 analog-to-digital/digital-to-analog interface (Axon Instruments, Union City, CA). Records were in addition stored on a Sony data recorder PC 204A (Racal Elektronik, Bergisch Gladbach, Germany). Further analysis was performed using self-written software in OriginPro version 7 (OriginLab Corporation, Northampton, MA) and MATLAB 6.5 (The MathWorks Inc., Natick, MA).
Data analysis was conducted as described previously.26 After close inspection of the data, a threshold was set manually to avoid artifacts produced by baseline noise. The mean firing rate was obtained from single-unit or multiunit recordings and defined as the number of action potentials above threshold divided by the recording time of 180 s. In addition to the effects of sevoflurane on mean firing rates, we normalized the data to eliminate acetylcholine-induced changes of the basal activity. The data were normalized by subtracting the firing rate monitored in the presence of sevoflurane from the control rate (absence of the anesthetic) for each experiment. The resulting difference was multiplied by 100 and divided by the control rate. Hence, a value of 0% indicates sevoflurane lacked any inhibitory drug action and a 100% depression indicates that not a single action potential occurred in the presence of the anesthetic.
Results are given as mean ± SEM. Concentration–response curves were fitted by Hill equations using OriginPro version 7. Estimated EC50values were derived from these fits. Statistical significance of differences between concentration–response curves were assessed via  an F test, as previously reported.14 For statistical analysis between two data groups, the Student t  test was used.
Results
Opposing Actions of Sevoflurane and Acetylcholine on Action Potential Activity
The effects of sevoflurane and acetylcholine on action potential activity monitored in neocortical slices are illustrated in figure 1. Both substances altered neuronal firing patterns as anticipated: action potential activity was decreased by sevoflurane but increased by acetylcholine (fig. 1A). The depression of neuronal activity caused by sevoflurane was displayed as a decrease in the frequency of bursts and a decrease in firing rates within these bursts (figs. 1B and C). Although the bursts were prolonged by the anesthetic, the overall time of neuronal silence was substantially lengthened. This pattern of sevoflurane effects on cortical network activity corresponds largely to the pattern observed with other ether anesthetics such as isoflurane and enflurane, as reported previously.13 Acetylcholine prolonged the duration of active states as observed with sevoflurane, but in contrast to the anesthetic, it increased average firing rates by elevating action potential activity within bursts (figs. 1C and D).
Fig. 1. Effects of sevoflurane and acetylcholine on action potential activity in neocortical slices. Sevoflurane data are depicted on the  left side  of the figure, and corresponding data obtained from experiments with acetylcholine are shown on the  right side  . (  A  ) Original recordings are displayed in the absence (  upper panel  ) and presence (  lower panel  ) of 0.26 mm sevoflurane (corresponding to 0.75 MAC [1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects]) and 0.3 μm acetylcholine. Corresponding binned data are shown in  B  and  C  . Spikes were binned at 50-ms intervals. The depression of neuronal activity caused by 0.75 MAC sevoflurane arose as a decrease in the frequency of episodes of ongoing activity and a decrease in firing rates within these episodes. Although the episodes of ongoing activity were prolonged by the anesthetic, the overall time of neuronal silence was substantially lengthened (  C  , left side  ). Acetylcholine prolonged the duration of active states as observed with sevoflurane, but in contrast to the anesthetic, it increased average firing rates by elevating action potential activity within episodes of ongoing activity (  C  , right side  ). (  D  ) Cumulative number of spikes over a recording period of 180 s. 
Fig. 1. Effects of sevoflurane and acetylcholine on action potential activity in neocortical slices. Sevoflurane data are depicted on the  left side  of the figure, and corresponding data obtained from experiments with acetylcholine are shown on the  right side  . (  A  ) Original recordings are displayed in the absence (  upper panel  ) and presence (  lower panel  ) of 0.26 mm sevoflurane (corresponding to 0.75 MAC [1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects]) and 0.3 μm acetylcholine. Corresponding binned data are shown in  B  and  C  . Spikes were binned at 50-ms intervals. The depression of neuronal activity caused by 0.75 MAC sevoflurane arose as a decrease in the frequency of episodes of ongoing activity and a decrease in firing rates within these episodes. Although the episodes of ongoing activity were prolonged by the anesthetic, the overall time of neuronal silence was substantially lengthened (  C  , left side  ). Acetylcholine prolonged the duration of active states as observed with sevoflurane, but in contrast to the anesthetic, it increased average firing rates by elevating action potential activity within episodes of ongoing activity (  C  , right side  ). (  D  ) Cumulative number of spikes over a recording period of 180 s. 
Fig. 1. Effects of sevoflurane and acetylcholine on action potential activity in neocortical slices. Sevoflurane data are depicted on the  left side  of the figure, and corresponding data obtained from experiments with acetylcholine are shown on the  right side  . (  A  ) Original recordings are displayed in the absence (  upper panel  ) and presence (  lower panel  ) of 0.26 mm sevoflurane (corresponding to 0.75 MAC [1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects]) and 0.3 μm acetylcholine. Corresponding binned data are shown in  B  and  C  . Spikes were binned at 50-ms intervals. The depression of neuronal activity caused by 0.75 MAC sevoflurane arose as a decrease in the frequency of episodes of ongoing activity and a decrease in firing rates within these episodes. Although the episodes of ongoing activity were prolonged by the anesthetic, the overall time of neuronal silence was substantially lengthened (  C  , left side  ). Acetylcholine prolonged the duration of active states as observed with sevoflurane, but in contrast to the anesthetic, it increased average firing rates by elevating action potential activity within episodes of ongoing activity (  C  , right side  ). (  D  ) Cumulative number of spikes over a recording period of 180 s. 
×
Concentration-dependent effects of sevoflurane and acetylcholine in neocortical and spinal tissue slices are depicted in figure 2. Levels of neuronal activity have been normalized to facilitate comparison. Sevoflurane reduced spontaneous activity of cortical and spinal neurons concentration-dependently within a range of clinically relevant concentrations. The anesthetic completely depressed neuronal activity at high concentrations in both preparations. Half-maximal effects were observed at 0.29 ± 0.01 mm in cortical and 0.17 ± 0.02 mm in spinal cultures corresponding to 0.83 ± 0.03 and 0.49 ± 0.05 MAC, respectively. The EC50value for depression of ongoing activity in spinal cultures obtained from mice turned out to be approximately 50% higher compared with the EC50value reported previously for rats (0.32 ± 0.01 MAC).26 In contrast to sevoflurane, acetylcholine increased firing rates in both cortical and spinal slices up to twofold to threefold. Cholinergic enhancement of action potential activity was more pronounced in cortical compared with spinal slices. Saturating effects were observed between 10 and 100 μm acetylcholine in both preparations.
Fig. 2. Concentration-dependent effects of sevoflurane and acetylcholine in neocortical and spinal tissue slices. Levels of neuronal activity have been normalized to facilitate comparison. Sevoflurane reduced spontaneous activity of cortical (  A  ) and spinal neurons (  B  ) concentration-dependently within a range of clinically relevant concentrations. The anesthetic completely depressed neuronal activity at high concentrations in both preparations. Half-maximal effects were observed at 0.29 ± 0.01 mm in cortical and 0.17 ± 0.02 mm in spinal cultures corresponding to 0.83 ± 0.03 MAC (1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects) and 0.49 ± 0.05 MAC, respectively. In contrast to sevoflurane, acetylcholine increased firing rates in both cortical (  C  ) and spinal slices (  D  ) up to twofold to threefold. Cholinergic enhancement of action potential activity was more pronounced in cortical compared with spinal slices. 
Fig. 2. Concentration-dependent effects of sevoflurane and acetylcholine in neocortical and spinal tissue slices. Levels of neuronal activity have been normalized to facilitate comparison. Sevoflurane reduced spontaneous activity of cortical (  A  ) and spinal neurons (  B  ) concentration-dependently within a range of clinically relevant concentrations. The anesthetic completely depressed neuronal activity at high concentrations in both preparations. Half-maximal effects were observed at 0.29 ± 0.01 mm in cortical and 0.17 ± 0.02 mm in spinal cultures corresponding to 0.83 ± 0.03 MAC (1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects) and 0.49 ± 0.05 MAC, respectively. In contrast to sevoflurane, acetylcholine increased firing rates in both cortical (  C  ) and spinal slices (  D  ) up to twofold to threefold. Cholinergic enhancement of action potential activity was more pronounced in cortical compared with spinal slices. 
Fig. 2. Concentration-dependent effects of sevoflurane and acetylcholine in neocortical and spinal tissue slices. Levels of neuronal activity have been normalized to facilitate comparison. Sevoflurane reduced spontaneous activity of cortical (  A  ) and spinal neurons (  B  ) concentration-dependently within a range of clinically relevant concentrations. The anesthetic completely depressed neuronal activity at high concentrations in both preparations. Half-maximal effects were observed at 0.29 ± 0.01 mm in cortical and 0.17 ± 0.02 mm in spinal cultures corresponding to 0.83 ± 0.03 MAC (1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects) and 0.49 ± 0.05 MAC, respectively. In contrast to sevoflurane, acetylcholine increased firing rates in both cortical (  C  ) and spinal slices (  D  ) up to twofold to threefold. Cholinergic enhancement of action potential activity was more pronounced in cortical compared with spinal slices. 
×
Intrinsic Release of Acetylcholine in Slice Cultures
The results presented so far do not provide an answer to the question whether acetylcholine is synthesized and released in cortical and spinal slice cultures. Therefore, we investigated the effects of the reversible acetylcholinesterase inhibitor neostigmine as well as atropine, a competitive antagonist at muscarinic receptors, on ongoing neuronal activity. In these experiments, acetylcholine was not added to the artificial cerebrospinal fluid. The results are summarized in figure 3. Neostigmine significantly increased action potential activity, demonstrating the existence of a cholinergic tone. The latter implication was corroborated by the finding that atropine reduced action potential firing of cortical and spinal neurons by approximately 50%. These experiments imply that the increase in ongoing neuronal activity evoked by bath applied acetylcholine (fig. 2) displays an effect generated on top of a basal tone caused by intrinsically released acetylcholine.
Fig. 3. Acetylcholine is released intrinsically in cortical and spinal tissue slices. The reversible acetylcholinesterase inhibitor neostigmine approximately doubled the firing rate at a concentration of 1 μm in cortical and spinal cultures, suggesting the existence of an intrinsic cholinergic release. This finding was corroborated by the observation that atropine, a competitive antagonist at muscarinic receptors, reduced action potential firing in both preparations by approximately 50%. 
Fig. 3. Acetylcholine is released intrinsically in cortical and spinal tissue slices. The reversible acetylcholinesterase inhibitor neostigmine approximately doubled the firing rate at a concentration of 1 μm in cortical and spinal cultures, suggesting the existence of an intrinsic cholinergic release. This finding was corroborated by the observation that atropine, a competitive antagonist at muscarinic receptors, reduced action potential firing in both preparations by approximately 50%. 
Fig. 3. Acetylcholine is released intrinsically in cortical and spinal tissue slices. The reversible acetylcholinesterase inhibitor neostigmine approximately doubled the firing rate at a concentration of 1 μm in cortical and spinal cultures, suggesting the existence of an intrinsic cholinergic release. This finding was corroborated by the observation that atropine, a competitive antagonist at muscarinic receptors, reduced action potential firing in both preparations by approximately 50%. 
×
Effects of Sevoflurane on Action Potential Activity in the Presence and Absence of Acetylcholine
Concentration-dependent effects of sevoflurane in the presence and absence of acetylcholine are presented in figure 4. Acetylcholine augmented neuronal firing rates in cortical slices at all sevoflurane concentrations tested, causing a concentration-dependent rightward and upward shift of the sevoflurane concentration response curve (fig. 4A). In spinal slices, enhancement of action potential activity caused by 10 μm acetylcholine appeared less pronounced compared with cortical slices (fig. 4B).
Fig. 4. Cholinergic modulation of sevoflurane effects on network activity in cortical and spinal slices. (  A  ) Acetylcholine augmented neuronal firing rates in cortical slices at all sevoflurane concentrations tested, causing a concentration-dependent rightward and upward shift of the sevoflurane concentration–response curve. (  B  ) In spinal slices, 10 μm acetylcholine produced a less pronounced increase in action potential activity. (  C  ) Cholinergic modulation of normalized data of action potential activity depressed by sevoflurane in cortical slices. Acetylcholine increased the EC50from 0.83 ± 0.03 MAC (1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects) in the absence of acetylcholine to 1.59 ± 0.32 MAC (1 μm acetylcholine) and 2.68 ± 0.57 MAC (10 μm acetylcholine). The concentration–response curves of sevoflurane measured in the presence of acetylcholine differed significantly from the concentration–response curve in the absence of acetylcholine (  P  < 0.001, F test). (  D  ) Acetylcholine did not reduce the potency of sevoflurane in depressing spinal neurons (0.49 ± 0.05 MAC in the absence compared with 0.47 ± 0.10 MAC in the presence of acetylcholine). The concentration–response curves did not differ significantly (  P  > 0.1, F test). 
Fig. 4. Cholinergic modulation of sevoflurane effects on network activity in cortical and spinal slices. (  A  ) Acetylcholine augmented neuronal firing rates in cortical slices at all sevoflurane concentrations tested, causing a concentration-dependent rightward and upward shift of the sevoflurane concentration–response curve. (  B  ) In spinal slices, 10 μm acetylcholine produced a less pronounced increase in action potential activity. (  C  ) Cholinergic modulation of normalized data of action potential activity depressed by sevoflurane in cortical slices. Acetylcholine increased the EC50from 0.83 ± 0.03 MAC (1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects) in the absence of acetylcholine to 1.59 ± 0.32 MAC (1 μm acetylcholine) and 2.68 ± 0.57 MAC (10 μm acetylcholine). The concentration–response curves of sevoflurane measured in the presence of acetylcholine differed significantly from the concentration–response curve in the absence of acetylcholine (  P  < 0.001, F test). (  D  ) Acetylcholine did not reduce the potency of sevoflurane in depressing spinal neurons (0.49 ± 0.05 MAC in the absence compared with 0.47 ± 0.10 MAC in the presence of acetylcholine). The concentration–response curves did not differ significantly (  P  > 0.1, F test). 
Fig. 4. Cholinergic modulation of sevoflurane effects on network activity in cortical and spinal slices. (  A  ) Acetylcholine augmented neuronal firing rates in cortical slices at all sevoflurane concentrations tested, causing a concentration-dependent rightward and upward shift of the sevoflurane concentration–response curve. (  B  ) In spinal slices, 10 μm acetylcholine produced a less pronounced increase in action potential activity. (  C  ) Cholinergic modulation of normalized data of action potential activity depressed by sevoflurane in cortical slices. Acetylcholine increased the EC50from 0.83 ± 0.03 MAC (1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects) in the absence of acetylcholine to 1.59 ± 0.32 MAC (1 μm acetylcholine) and 2.68 ± 0.57 MAC (10 μm acetylcholine). The concentration–response curves of sevoflurane measured in the presence of acetylcholine differed significantly from the concentration–response curve in the absence of acetylcholine (  P  < 0.001, F test). (  D  ) Acetylcholine did not reduce the potency of sevoflurane in depressing spinal neurons (0.49 ± 0.05 MAC in the absence compared with 0.47 ± 0.10 MAC in the presence of acetylcholine). The concentration–response curves did not differ significantly (  P  > 0.1, F test). 
×
Further interactions between acetylcholine and sevoflurane were characterized by normalizing the changes in neuronal activity caused by the anesthetic in the absence and presence of acetylcholine (see Materials and Methods). The plots in figures 4C and Dshow the concentration-dependent effects of sevoflurane ranging to 100% inhibition, corresponding to a total depression of firing rates in both preparations. In cortical slices, acetylcholine attenuated sevoflurane potency in a concentration-dependent manner. The EC50was increased from 0.83 ± 0.03 MAC (0 μm acetylcholine) to 1.59 ± 0.32 MAC (1 μm acetylcholine) and 2.68 ± 0.57 MAC (10 μm acetylcholine) (fig. 4Cand table 1). Both concentration–response curves of sevoflurane measured in the presence of acetylcholine differed significantly from the concentration–response curve in the absence of acetylcholine (P  < 0.001, F test). In contrast to neocortical networks, acetylcholine did not reduce the potency of sevoflurane in depressing spinal neurons (0.49 ± 0.05 MAC in the absence compared with 0.47 ± 0.10 MAC in the presence of acetylcholine; fig. 4Dand table 1). The concentration–response curves did not differ significantly (P  > 0.1, F test).
Table 1. Parameters of Sevoflurane Concentration–Response Curves Measured in the Absence and Presence of Acetylcholine in Cultured Cortical and Spinal Slices 
Image not available
Table 1. Parameters of Sevoflurane Concentration–Response Curves Measured in the Absence and Presence of Acetylcholine in Cultured Cortical and Spinal Slices 
×
Effects of Sevoflurane in Cortical and Spinal Slices in the Presence of Bicuculline
How can we explain the finding that acetylcholine reduces sevoflurane potency in cortical but not in spinal neurons? We hypothesized that this difference is related to distinct molecular targets of sevoflurane in cortical and spinal networks as well as to acetylcholine-induced changes in the efficacy of GABAAreceptor–mediated inhibition. In particular, we hypothesized that sevoflurane depresses neuronal activity in cortical networks predominantly via  enhancing GABAAreceptor function, as demonstrated previously for isoflurane and enflurane.13 In contrast to the neocortex, GABAAreceptors are only a minor target of sevoflurane in the spinal cord.26,32,33 
This hypothesis was tested as follows: Quantitative effects of acetylcholine were mimicked in spinal and neocortical slices by applying bicuculline, a specific GABAAreceptor antagonist. Thereby, two effects exerted by acetylcholine were simulated, namely an increase in neuronal activity and a decrease in the efficacy of GABAAreceptor–mediated inhibition. According to the hypothesis proposed in the last paragraph, bicuculline is expected to decrease sevoflurane potency in cortical but not in spinal slices. A concentration of 1 μm bicuculline was used in the experiments because it approximately doubled ongoing neuronal activity in cultured cortical and spinal slices (fig. 5A) and can consequently be regarded as equipotent with regard to the effects on network activity induced by acetylcholine. In neocortical slices, bicuculline induced an increase in EC50of sevoflurane from 0.83 ± 0.03 to 1.44 ± 0.26 MAC (fig. 5B). Both concentration–response curves differed significantly (P  < 0.01, F test). In contrast to the neocortex, bicuculline did not significantly reduce the potency of sevoflurane in depressing spinal neurons (0.49 ± 0.05 MAC in the absence compared with 0.42 ± 0.05 MAC in the presence of bicuculline; fig. 5C). In accord with the EC50values, the concentration–response curves were not different (P  > 0.1, F test).
Fig. 5. Bicuculline effects on the potency of sevoflurane in depressing neuronal network activity in cortical and spinal slices. (  A  ) Action potential activity was approximately doubled by 1 μm bicuculline in both preparations in the absence of sevoflurane (*  P  < 0.05,  t  test, n = 10). (  B  ) In neocortical slices, 1 μm bicuculline induced an increase in EC50of sevoflurane from 0.83 ± 0.03 MAC (1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects) to 1.44 ± 0.26 MAC. Both concentration–response curves differed significantly (  P  < 0.01, F test). (  C  ) In contrast to neocortical slices, bicuculline did not affect the potency of sevoflurane in depressing spinal neurons (0.49 ± 0.05 MAC in the absence compared with 0.42 ± 0.05 MAC in the presence of bicuculline). In accord with the EC50values, the concentration–response curves were not different (  P  > 0.1, F test). 
Fig. 5. Bicuculline effects on the potency of sevoflurane in depressing neuronal network activity in cortical and spinal slices. (  A  ) Action potential activity was approximately doubled by 1 μm bicuculline in both preparations in the absence of sevoflurane (*  P  < 0.05,  t  test, n = 10). (  B  ) In neocortical slices, 1 μm bicuculline induced an increase in EC50of sevoflurane from 0.83 ± 0.03 MAC (1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects) to 1.44 ± 0.26 MAC. Both concentration–response curves differed significantly (  P  < 0.01, F test). (  C  ) In contrast to neocortical slices, bicuculline did not affect the potency of sevoflurane in depressing spinal neurons (0.49 ± 0.05 MAC in the absence compared with 0.42 ± 0.05 MAC in the presence of bicuculline). In accord with the EC50values, the concentration–response curves were not different (  P  > 0.1, F test). 
Fig. 5. Bicuculline effects on the potency of sevoflurane in depressing neuronal network activity in cortical and spinal slices. (  A  ) Action potential activity was approximately doubled by 1 μm bicuculline in both preparations in the absence of sevoflurane (*  P  < 0.05,  t  test, n = 10). (  B  ) In neocortical slices, 1 μm bicuculline induced an increase in EC50of sevoflurane from 0.83 ± 0.03 MAC (1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects) to 1.44 ± 0.26 MAC. Both concentration–response curves differed significantly (  P  < 0.01, F test). (  C  ) In contrast to neocortical slices, bicuculline did not affect the potency of sevoflurane in depressing spinal neurons (0.49 ± 0.05 MAC in the absence compared with 0.42 ± 0.05 MAC in the presence of bicuculline). In accord with the EC50values, the concentration–response curves were not different (  P  > 0.1, F test). 
×
In the following step, we investigated whether the depressant effects of sevoflurane in neocortical slices can be completely antagonized by higher bicuculline concentrations (100 μm) as reported previously for other ether derivates.34 A concentration of 100 μm bicuculline abolished the depression of neuronal network activity by 0.26 mm (corresponding to 0.75 MAC) sevoflurane almost completely (from 49.61 ± 3.41% in the absence to 2.87 ± 5.13% in the presence of bicuculline; P  < 0.001, n = 10). This result points to enhanced GABAergic synaptic inhibition being the predominant mechanism mediating the depressant effects of 0.75 MAC sevoflurane in neocortical slices (fig. 6).
Fig. 6. Effects of 0.75 MAC sevoflurane (1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects) in the absence and presence of 100 μm bicuculline. A concentration of 100 μm bicuculline abolished the depression of neuronal network activity by 0.26 mm (corresponding to 0.75 MAC) sevoflurane almost completely (from 49.61 ± 3.41% in the absence to 2.87 ± 5.13% in the presence of bicuculline; ***  P  < 0.001,  t  test, n = 10). This result points to enhanced synaptic inhibition mediated  via  γ-aminobutyric acid type A receptors being the predominate mechanism to cause the depressant effects of 0.75 MAC sevoflurane in neocortical slices. 
Fig. 6. Effects of 0.75 MAC sevoflurane (1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects) in the absence and presence of 100 μm bicuculline. A concentration of 100 μm bicuculline abolished the depression of neuronal network activity by 0.26 mm (corresponding to 0.75 MAC) sevoflurane almost completely (from 49.61 ± 3.41% in the absence to 2.87 ± 5.13% in the presence of bicuculline; ***  P  < 0.001,  t  test, n = 10). This result points to enhanced synaptic inhibition mediated  via  γ-aminobutyric acid type A receptors being the predominate mechanism to cause the depressant effects of 0.75 MAC sevoflurane in neocortical slices. 
Fig. 6. Effects of 0.75 MAC sevoflurane (1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects) in the absence and presence of 100 μm bicuculline. A concentration of 100 μm bicuculline abolished the depression of neuronal network activity by 0.26 mm (corresponding to 0.75 MAC) sevoflurane almost completely (from 49.61 ± 3.41% in the absence to 2.87 ± 5.13% in the presence of bicuculline; ***  P  < 0.001,  t  test, n = 10). This result points to enhanced synaptic inhibition mediated  via  γ-aminobutyric acid type A receptors being the predominate mechanism to cause the depressant effects of 0.75 MAC sevoflurane in neocortical slices. 
×
Effects of Acetylcholine on Etomidate Potency in Cortical and Spinal Slices
In the last set of experiments, the interactions between sevoflurane and bicuculline were studied to elucidate how a decrease in GABAAreceptor–mediated inhibition alters the potency of sevoflurane in cortical and spinal networks. The results displayed in figure 5support the proposed mechanism that acetylcholine attenuates the impact of GABAergic inhibition. To corroborate this hypothesis, the effects of etomidate, an almost selective modulator at GABAAreceptors, were investigated. The selectivity of etomidate at GABAAreceptors has been demonstrated previously for both cortical and spinal networks in vitro  and in vivo  .35,36 Therefore, the hypothesis to be tested was that acetylcholine reduces the relative inhibition of neuronal activity exerted by etomidate not only in cortical but also in spinal slices. Effects of etomidate on cortical and spinal neurons were investigated at a concentration of 1.5 μm. This concentration decreased neuronal activity by approximately 60% in both cortical and spinal networks in the absence of acetylcholine. In cortical slices, the relative inhibition in the presence of acetylcholine was reduced from 63.4 ± 6.8 to 29.7 ± 13.7% (n = 10, P  < 0.05), whereas acetylcholine decreased the relative inhibition of 1.5 μm etomidate to depress spinal neurons from 65.5 ± 3.9% to 47.0 ± 4.1% (n = 8, P  < 0.01). The results clearly demonstrate that in contrast to sevoflurane, the relative inhibition of etomidate was reduced not only in cortical but also in spinal networks, supporting the hypothesis that acetylcholine attenuates the impact of GABAergic inhibition in both preparations.
Discussion
Mechanisms Underlying Cholinergic-induced Decrease in Sevoflurane Potency
The cholinergic system is an important modulatory neurotransmitter system in the brain.37 Activation of cholinergic innervation of the cortex has been implicated in sensory processing, learning, and memory. The application of the reversible acetylcholinesterase inhibitor tacrine has been demonstrated to promote plasticity and learning in the motor cortex of healthy volunteers.38 At the cellular level, high concentrations of the cholinergic agonist carbachol have been shown to have a strong desynchronizing action on neuronal activity measured in cultured cortical neurons.39 In layer V of the rat visual cortex, acetylcholine both increases excitability and depresses synaptic transmission by affecting different GABAergic interneurons via  distinct cholinergic receptors.40 Furthermore, there is ample evidence that cholinergic stimulation decreases GABA release in cortical networks by activating muscarinic and nicotinic receptors located on presynaptic terminals.9,10 
Moreover, interactions of reversible and irreversible blockers of acetylcholinesterase with muscarinic receptors affect GABAergic transmission in hippocampal neurons in vitro  .41 But how will a decrease in GABA release alter anesthetic mechanisms? We predict that the potency of GABAergic anesthetics in depressing neuronal network activity is quantitatively linked to the extracellular GABA concentration. This hypothesis is based on the fact that at clinically relevant concentrations, anesthetics frequently act as positive modulators at GABAAreceptors. Therefore, they require the presence of GABA at the agonist binding site for affecting GABAAreceptor function.42–44 The experimental finding that acetylcholine impairs the potency of sevoflurane in decreasing neuronal activity in cortical slices is therefore well explained by a modulatory action of sevoflurane at GABAAreceptors.
Unlike in neocortex, sevoflurane potency remained unaffected by acetylcholine in spinal cord slices. What is the reason for this brain region–specific difference? In the current study, we have provided evidence that the GABAAreceptor is a major target for sevoflurane in neocortical microcircuits. However, we recently demonstrated that in cultured spinal slices sevoflurane depresses neuronal activity via  multiple molecular targets and that modulation of GABAAreceptors is not the major mechanism by which sevoflurane decreases the excitability of spinal neurons.26 The different actions of sevoflurane on neocortical and spinal networks are clearly shown in figure 5. The specific GABAAreceptor antagonist bicuculline increases neuronal basal activity at a concentration of 1 μm in neocortical and spinal slices by approximately twofold, indicating that in both networks action potential firing is under substantial GABAergic control. However, bicuculline reduces sevoflurane potency only in neocortical slices, supporting the hypothesis that acetylcholine affects sevoflurane potency just minimally in spinal slices because GABAAreceptors are not a predominant target of the anesthetic.
However, the finding that acetylcholine did not affect the potency of sevoflurane in depressing action potential firing of spinal slices can alternatively be explained by assuming that acetylcholine does not affect GABAAreceptor–mediated inhibition in the spinal cord. To rule out this possibility, interactions between acetylcholine and the almost selective GABAAreceptors modulator etomidate were investigated, hypothesizing that acetylcholine did not affect etomidate potency in spinal slices. The hypothesis had to be abandoned because acetylcholine decreased the potency of etomidate in both spinal and cortical networks. The finding that acetylcholine significantly affects etomidate potency in spinal slices clearly argues against the possibility that acetylcholine does not modulate GABAAreceptor–mediated inhibition in the spinal cord.
Brain Acetylcholine Concentration during Cholinergic Crisis
The brain acetylcholine concentrations occurring during a severe organophosphate intoxication are hard to measure in vivo  . However, in an outstanding study, Tonduli et al  .3 exposed freely moving rats to soman and acquired three sets of neurophysiologic data before and during the intoxication. They determined cortical acetylcholinesterase activity and acetylcholine concentrations by microdialysis and associated the parameters with electroencephalographic recordings as well as with power spectrum analysis of the γ band. Acetylcholine levels measured in 60-μl microdialysis fractions obtained from intoxicated rats ranged from 40 ± 8 pmol in subjects showing no seizure activity to 102 ± 21 pmol in rats displaying severe seizure activity,3 corresponding to concentrations of 0.7 and 1.7 μm in the perfusate of the fraction, respectively. The concentration in extracellular space is always higher compared with the perfusate concentration, depending on the type of probe and the perfusion speed. In the study performed by Tonduli et al  ., the microdialysis probes were perfused with 2 μl/min, and a fraction was collected every 30 min. With this perfusion speed, a relative recovery of 20% can be assumed, leading to concentrations between 3.5 and 8.5 μm in the extracellular space depending on the degree of soman intoxication. Therefore, the concentrations of 1 and 10 μm used in our experiments cover well the range of extracellular acetylcholine concentrations observed in intoxicated rats.
Cholinergic Modulation of Drug Requirement for Providing Anesthesia
In an elegant study, Hudetz et al  .45 recently showed that neostigmine, a reversal blocker of acetylcholinesterase, inverts isoflurane-induced hypnosis in rats. In addition to these results, there is multiple evidence that cholinesterase blockers reverse anesthesia by increasing brain acetylcholine levels.46,47 In the current study, we identified two putative mechanisms: First, we observed that acetylcholine increases neuronal basal activity in spinal and cortical slices by twofold to threefold (fig. 2). Because general anesthesia is based on a severe depression of central nervous functions, the excitatory actions exerted by acetylcholine must be counterbalanced by increasing anesthetic concentrations. Second, we showed that acetylcholine compromises anesthetic potency, a finding that is probably explained by an impairment of GABAAreceptor–mediated inhibition. Both mechanisms, namely the elevation of neuronal basal activity (fig. 4) and the decrease in anesthetic potency, may significantly increase drug requirement for providing general anesthesia in patients with organophosphate intoxication. The pharmacologic management of organophosphate poisoning has extensively been discussed by Lallement et al  .48,49 Remarkably, benzodiazepines such as diazepam, which are potent modulators of GABAAreceptors, are recommended for acute treatment of epileptiform seizure activity in intoxicated patients.7,49 In rats, diazepam interrupts soman-induced seizures only when applied within the first 5–10 min after seizure onset.50 It seems likely that a severe decrease in the potency of diazepam as caused by massive cholinergic overstimulation may attribute to this temporally limited effect.
The conclusion that cholinergic stimulation increases drug requirement for providing anesthesia is also corroborated by human studies using a reversible inhibitor of acetylcholinesterase. Meuret et al  .47 investigated the effects of physostigmine in human subjects anesthetized with propofol by assessing central nervous system function by use of the Auditory Steady State Response and Bispectral Index. Physostigmine restored consciousness with concomitant increases in the Auditory Steady State Response and Bispectral Index. Using a similar experimental approach, Plourde et al  .51 report that sevoflurane anesthesia is also antagonized by physostigmine.
In summary, the studies on the effects of anticholinesterases on experimental animals and human subjects clearly indicate that cholinergic overstimulation may considerably increase drug requirement for providing general anesthesia. However, raising anesthetic concentrations into a high-dose range in patients with organophosphorus intoxication may not always be an option, because these patients frequently display cardiac abnormalities and hemodynamic instability.1,7 An alternative treatment may be the coapplication of anesthetics and antagonists of muscarinic acetylcholine receptors such as atropine. The rational for this option is that acetylcholine-induced reversal of hypnosis is largely mediated via  muscarinic receptors. Hudetz et al  .45 demonstrated that muscarinic agonists mimic the effects of anticholinesterases on the righting reflex and the electroencephalogram. This finding is corroborated by the observation of Douglas et al  .52,53 that cholinergic electroencephalographic arousal is largely mediated by M1 and M2 receptors. Without blocking muscarinic receptors, anesthesiologists may be unable to determine anesthetic requirement because acetylcholine concentrations in the central nervous system are unknown and may undergo gross changes in patients with organophosphorus intoxication. However, more direct studies to test these ideas in whole animals are required before recommendations for approaches to clinical care can be made.
The authors thank Claudia Holt (Technical Assistant, Eberhard-Karls-University, Tuebingen, Germany) for excellent technical assistance.
References
Ben Abraham R, Rudick V, Weinbroum AA: Practical guidelines for acute care of victims of bioterrorism: Conventional injuries and concomitant nerve agent intoxication. Anesthesiology 2002; 97:989–1004Ben Abraham, R Rudick, V Weinbroum, AA
Lallement G, Denoyer M, Collet A, Pernot MI, Baubichon D, Monmaur P, Blanchet G: Changes in hippocampal acetylcholine and glutamate extracellular levels during soman-induced seizures: Influence of septal cholinoceptive cells. Neurosci Lett 1992; 139:104–7Lallement, G Denoyer, M Collet, A Pernot, MI Baubichon, D Monmaur, P Blanchet, G
Tonduli LS, Testylier G, Marino IP, Lallement G: Triggering of soman-induced seizures in rats: Multiparametric analysis with special correlation between enzymatic, neurochemical and electrophysiological data. J Neurosci Res 1999; 58:464–73Tonduli, LS Testylier, G Marino, IP Lallement, G
de Jong RH: Nerve gas terrorism: A grim challenge to anesthesiologists. Anesth Analg 2003; 96:819–25de Jong, RH
Cosar A, Kenar L: An anesthesiological approach to nerve agent victims. Mil Med 2006; 171:7–11Cosar, A Kenar, L
Eddleston M, Phillips MR: Self poisoning with pesticides. BMJ 2004; 328:42–4Eddleston, M Phillips, MR
White SM: Chemical and biological weapons: Implications for anaesthesia and intensive care. Br J Anaesth 2002; 89:306–24White, SM
Baker DJ: Management of casualties from terrorist chemical and biological attack: A key role for the anaesthetist. Br J Anaesth 2002; 89:211–4Baker, DJ
Hashimoto T, Shu H, Kuriyama K: Muscarinic M1 receptor mediated inhibition of GABA release from rat cerebral cortex. Neurochem Int 1994; 24:389–94Hashimoto, T Shu, H Kuriyama, K
Yamazaki Y, Jia Y, Hamaue N, Sumikawa K: Nicotine-induced switch in the nicotinic cholinergic mechanisms of facilitation of long-term potentiation induction. Eur J Neurosci 2005; 22:845–60Yamazaki, Y Jia, Y Hamaue, N Sumikawa, K
Kohling R, Vreugdenhil M, Bracci E, Jefferys JG: Ictal epileptiform activity is facilitated by hippocampal GABAA receptor-mediated oscillations. J Neurosci 2000; 20:6820–9Kohling, R Vreugdenhil, M Bracci, E Jefferys, JG
Thompson SM, Gahwiler BH: Activity-dependent disinhibition: I. Repetitive stimulation reduces IPSP driving force and conductance in the hippocampus in vitro  . J Neurophysiol 1989; 61:501–11Thompson, SM Gahwiler, BH
Antkowiak B, Helfrich FC: Effects of small concentrations of volatile anesthetics on action potential firing of neocortical neurons in vitro  . Anesthesiology 1998; 88:1592–605Antkowiak, B Helfrich, FC
Hentschke H, Schwarz C, Antkowiak B: Neocortex is the major target of sedative concentrations of volatile anaesthetics: Strong depression of firing rates and increase of GABA receptor-mediated inhibition. Eur J Neurosci 2005; 21:93–102Hentschke, H Schwarz, C Antkowiak, B
Fiset P, Paus T, Daloze T, Plourde G, Meuret P, Bonhomme V, Hajj AN, Backman SB, Evans AC: Brain mechanisms of propofol-induced loss of consciousness in humans: A positron emission tomographic study. J Neurosci 1999; 19:5506–13Fiset, P Paus, T Daloze, T Plourde, G Meuret, P Bonhomme, V Hajj, AN Backman, SB Evans, AC
Grasshoff C, Rudolph U, Antkowiak B: Molecular and systemic mechanisms of general anaesthesia: The “multi-site and multiple mechanisms” concept. Curr Opin Anaesthesiol 2005; 18:386–91Grasshoff, C Rudolph, U Antkowiak, B
Rudolph U, Antkowiak B: Molecular and neuronal substrates for general anaesthetics. Nat Rev Neurosci 2004; 5:709–20Rudolph, U Antkowiak, B
Collins JG, Kendig JJ, Mason P: Anesthetic actions within the spinal cord: Contributions to the state of general anesthesia. Trends Neurosci 1995; 18:549–53Collins, JG Kendig, JJ Mason, P
Campagna JA, Miller KW, Forman SA: Mechanisms of actions of inhaled anesthetics. N Engl J Med 2003; 348:2110–24Campagna, JA Miller, KW Forman, SA
Sonner JM, Antognini JF, Dutton RC, Flood P, Gray AT, Harris RA, Homanics GE, Kendig J, Orser B, Raines DE, Trudell J, Vissel B, Eger EI: Inhaled anesthetics and immobility: Mechanisms, mysteries, and minimum alveolar anesthetic concentration. Anesth Analg 2003; 97:718–40Sonner, JM Antognini, JF Dutton, RC Flood, P Gray, AT Harris, RA Homanics, GE Kendig, J Orser, B Raines, DE Trudell, J Vissel, B Eger, EI
Braschler UF, Iannone A, Spenger C, Streit J, Luscher HR: A modified roller tube technique for organotypic cocultures of embryonic rat spinal cord, sensory ganglia and skeletal muscle. J Neurosci Methods 1989; 29:121–9Braschler, UF Iannone, A Spenger, C Streit, J Luscher, HR
Drexler B, Roether CL, Jurd R, Rudolph U, Antkowiak B: Opposing actions of etomidate on cortical theta oscillations are mediated by different γ-aminobutyric acid type A receptor subtypes. Anesthesiology 2005; 102:346–52Drexler, B Roether, CL Jurd, R Rudolph, U Antkowiak, B
Drexler B, Jurd R, Rudolph U, Antkowiak B: Dual actions of enflurane on postsynaptic currents abolished by the γ-aminobutyric acid type A receptor β3(N265M) point mutation. Anesthesiology 2006; 105:297–304Drexler, B Jurd, R Rudolph, U Antkowiak, B
Gahwiler BH: Organotypic monolayer cultures of nervous tissue. J Neurosci Methods 1981; 4:329–42Gahwiler, BH
Antkowiak B: Different actions of general anesthetics on the firing patterns of neocortical neurons mediated by the GABAAreceptor. Anesthesiology 1999; 91:500–11Antkowiak, B
Grasshoff C, Antkowiak B: Propofol and sevoflurane depress spinal neurons in vitro  via  different molecular targets. Anesthesiology 2004; 101:1167–76Grasshoff, C Antkowiak, B
Streit J, Spenger C, Luscher HR: An organotypic spinal cord–dorsal root ganglion–skeletal muscle coculture of embryonic rat: II. Functional evidence for the formation of spinal reflex arcs in vitro  . Eur J Neurosci 1991; 3:1054–68Streit, J Spenger, C Luscher, HR
Spenger-C, Braschler UF, Streit J, Luscher HR: An organotypic spinal cord–dorsal root ganglion skeletal muscle coculture of embryonic rat: I. The morphological correlates of the spinal reflex arc. Eur J Neurosci 1991; 3:1037–53
Ballerini L, Galante M: Network bursting by organotypic spinal slice cultures in the presence of bicuculline and/or strychnine is developmentally regulated. Eur J Neurosci 1998; 10:2871–9Ballerini, L Galante, M
Franks NP, Lieb WR: Molecular and cellular mechanisms of general anaesthesia. Nature 1994; 367:607–14Franks, NP Lieb, WR
Antkowiak B, Heck D: Effects of the volatile anesthetic enflurane on spontaneous discharge rate and GABA(A)-mediated inhibition of Purkinje cells in rat cerebellar slices. J Neurophysiol 1997; 77:2525–38Antkowiak, B Heck, D
Zhang Y, Wu S, Eger EI, Sonner JM: Neither GABA(A) nor strychnine-sensitive glycine receptors are the sole mediators of MAC for isoflurane. Anesth Analg 2001; 92:123–7Zhang, Y Wu, S Eger, EI Sonner, JM
Zhang Y, Sonner JM, Eger EI, Stabernack CR, Laster MJ, Raines DE, Harris RA: Gamma-aminobutyric acid A receptors do not mediate the immobility produced by isoflurane. Anesth Analg 2004; 99:85–90Zhang, Y Sonner, JM Eger, EI Stabernack, CR Laster, MJ Raines, DE Harris, RA
Antkowiak B, Hentschke H, Kirschfeld K: Effects of volatile anaesthetics on spontaneous action potential firing of cerebellar Purkinje cells in vitro  do not follow the Meyer-Overton rule. Br J Anaesth 1997; 79:617–24Antkowiak, B Hentschke, H Kirschfeld, K
Grasshoff C, Jurd R, Rudolph U, Antkowiak B: Spinal β3-containing GABAAreceptors mediate pre- and postsynaptic effects of etomidate (abstract). Anesthesiology 2006; 105:A1115Grasshoff, C Jurd, R Rudolph, U Antkowiak, B
Jurd R, Arras M, Lambert S, Drexler B, Siegwart R, Crestani F, Zaugg M, Vogt KE, Ledermann B, Antkowiak B, Rudolph U: General anesthetic actions in vivo  strongly attenuated by a point mutation in the GABA(A) receptor beta3 subunit. FASEB J 2003; 17:250–2Jurd, R Arras, M Lambert, S Drexler, B Siegwart, R Crestani, F Zaugg, M Vogt, KE Ledermann, B Antkowiak, B Rudolph, U
Perry E, Walker M, Grace J, Perry R: Acetylcholine in mind: A neurotransmitter correlate of consciousness? Trends Neurosci 1999; 22:273–80Perry, E Walker, M Grace, J Perry, R
Korchounov A, Ilic TV, Schwinge T, Ziemann U: Modification of motor cortical excitability by an acetylcholinesterase inhibitor. Exp Brain Res 2005; 164:399–405Korchounov, A Ilic, TV Schwinge, T Ziemann, U
Tateno T, Jimbo Y, Robinson HP: Spatio-temporal cholinergic modulation in cultured networks of rat cortical neurons: Spontaneous activity. Neuroscience 2005; 134:425–37Tateno, T Jimbo, Y Robinson, HP
Xiang Z, Huguenard JR, Prince DA: Cholinergic switching within neocortical inhibitory networks. Science 1998; 281:985–8Xiang, Z Huguenard, JR Prince, DA
Santos MD, Pereira EF, Aracava Y, Castro NG, Fawcett WP, Randall WR, Albuquerque EX: Low concentrations of pyridostigmine prevent soman-induced inhibition of GABAergic transmission in the central nervous system: Involvement of muscarinic receptors. J Pharmacol Exp Ther 2003; 304:254–65Santos, MD Pereira, EF Aracava, Y Castro, NG Fawcett, WP Randall, WR Albuquerque, EX
Li X, Czajkowski C, Pearce RA: Rapid and direct modulation of GABAAreceptors by halothane. Anesthesiology 2000; 92:1366–75Li, X Czajkowski, C Pearce, RA
Li X, Pearce RA: Effects of halothane on GABA(A) receptor kinetics: Evidence for slowed agonist unbinding. J Neurosci 2000; 20:899–907Li, X Pearce, RA
Lin LH, Chen LL, Zirrolli JA, Harris RA: General anesthetics potentiate gamma-aminobutyric acid actions on gamma-aminobutyric acid A receptors expressed by Xenopus  oocytes: Lack of involvement of intracellular calcium. J Pharmacol Exp Ther 1992; 263:569–78Lin, LH Chen, LL Zirrolli, JA Harris, RA
Hudetz AG, Wood JD, Kampine JP: Cholinergic reversal of isoflurane anesthesia in rats as measured by cross-approximate entropy of the electroencephalogram. Anesthesiology 2003; 99:1125–31Hudetz, AG Wood, JD Kampine, JP
Fassoulaki A, Sarantopoulos C, Derveniotis C: Physostigmine increases the dose of propofol required to induce anaesthesia. Can J Anaesth 1997; 44:1148–51Fassoulaki, A Sarantopoulos, C Derveniotis, C
Meuret P, Backman SB, Bonhomme V, Plourde G, Fiset P: Physostigmine reverses propofol-induced unconsciousness and attenuation of the auditory steady state response and Bispectral Index in human volunteers. Anesthesiology 2000; 93:708–17Meuret, P Backman, SB Bonhomme, V Plourde, G Fiset, P
Lallement G, Dorandeu F, Filliat P, Carpentier P, Baille V, Blanchet G: Medical management of organophosphate-induced seizures. J Physiol Paris 1998; 92:369–73Lallement, G Dorandeu, F Filliat, P Carpentier, P Baille, V Blanchet, G
Lallement G, Baubichon D, Clarencon D, Galonnier M, Peoc’h M, Carpentier P: Review of the value of gacyclidine (GK-11) as adjuvant medication to conventional treatments of organophosphate poisoning: Primate experiments mimicking various scenarios of military or terrorist attack by soman. Neurotoxicology 1999; 20:675–84Lallement, G Baubichon, D Clarencon, D Galonnier, M Peoc’h, M Carpentier, P
Shih T, McDonough-JH J, Koplovitz I: Anticonvulsants for soman-induced seizure activity. J Biomed Sci 1999; 6:86–96Shih, T McDonough-JH, J Koplovitz, I
Plourde G, Chartrand D, Fiset P, Font S, Backman SB: Antagonism of sevoflurane anaesthesia by physostigmine: Effects on the auditory steady-state response and bispectral index. Br J Anaesth 2003; 91:583–6Plourde, G Chartrand, D Fiset, P Font, S Backman, SB
Douglas CL, Baghdoyan HA, Lydic R: Postsynaptic muscarinic M1 receptors activate prefrontal cortical EEG of C57BL/6J mouse. J Neurophysiol 2002; 88:3003–9Douglas, CL Baghdoyan, HA Lydic, R
Douglas CL, Baghdoyan HA, Lydic R: Prefrontal cortex acetylcholine release, EEG slow waves, and spindles are modulated by M2 autoreceptors in C57BL/6J mouse. J Neurophysiol 2002; 87:2817–22Douglas, CL Baghdoyan, HA Lydic, R
Fig. 1. Effects of sevoflurane and acetylcholine on action potential activity in neocortical slices. Sevoflurane data are depicted on the  left side  of the figure, and corresponding data obtained from experiments with acetylcholine are shown on the  right side  . (  A  ) Original recordings are displayed in the absence (  upper panel  ) and presence (  lower panel  ) of 0.26 mm sevoflurane (corresponding to 0.75 MAC [1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects]) and 0.3 μm acetylcholine. Corresponding binned data are shown in  B  and  C  . Spikes were binned at 50-ms intervals. The depression of neuronal activity caused by 0.75 MAC sevoflurane arose as a decrease in the frequency of episodes of ongoing activity and a decrease in firing rates within these episodes. Although the episodes of ongoing activity were prolonged by the anesthetic, the overall time of neuronal silence was substantially lengthened (  C  , left side  ). Acetylcholine prolonged the duration of active states as observed with sevoflurane, but in contrast to the anesthetic, it increased average firing rates by elevating action potential activity within episodes of ongoing activity (  C  , right side  ). (  D  ) Cumulative number of spikes over a recording period of 180 s. 
Fig. 1. Effects of sevoflurane and acetylcholine on action potential activity in neocortical slices. Sevoflurane data are depicted on the  left side  of the figure, and corresponding data obtained from experiments with acetylcholine are shown on the  right side  . (  A  ) Original recordings are displayed in the absence (  upper panel  ) and presence (  lower panel  ) of 0.26 mm sevoflurane (corresponding to 0.75 MAC [1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects]) and 0.3 μm acetylcholine. Corresponding binned data are shown in  B  and  C  . Spikes were binned at 50-ms intervals. The depression of neuronal activity caused by 0.75 MAC sevoflurane arose as a decrease in the frequency of episodes of ongoing activity and a decrease in firing rates within these episodes. Although the episodes of ongoing activity were prolonged by the anesthetic, the overall time of neuronal silence was substantially lengthened (  C  , left side  ). Acetylcholine prolonged the duration of active states as observed with sevoflurane, but in contrast to the anesthetic, it increased average firing rates by elevating action potential activity within episodes of ongoing activity (  C  , right side  ). (  D  ) Cumulative number of spikes over a recording period of 180 s. 
Fig. 1. Effects of sevoflurane and acetylcholine on action potential activity in neocortical slices. Sevoflurane data are depicted on the  left side  of the figure, and corresponding data obtained from experiments with acetylcholine are shown on the  right side  . (  A  ) Original recordings are displayed in the absence (  upper panel  ) and presence (  lower panel  ) of 0.26 mm sevoflurane (corresponding to 0.75 MAC [1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects]) and 0.3 μm acetylcholine. Corresponding binned data are shown in  B  and  C  . Spikes were binned at 50-ms intervals. The depression of neuronal activity caused by 0.75 MAC sevoflurane arose as a decrease in the frequency of episodes of ongoing activity and a decrease in firing rates within these episodes. Although the episodes of ongoing activity were prolonged by the anesthetic, the overall time of neuronal silence was substantially lengthened (  C  , left side  ). Acetylcholine prolonged the duration of active states as observed with sevoflurane, but in contrast to the anesthetic, it increased average firing rates by elevating action potential activity within episodes of ongoing activity (  C  , right side  ). (  D  ) Cumulative number of spikes over a recording period of 180 s. 
×
Fig. 2. Concentration-dependent effects of sevoflurane and acetylcholine in neocortical and spinal tissue slices. Levels of neuronal activity have been normalized to facilitate comparison. Sevoflurane reduced spontaneous activity of cortical (  A  ) and spinal neurons (  B  ) concentration-dependently within a range of clinically relevant concentrations. The anesthetic completely depressed neuronal activity at high concentrations in both preparations. Half-maximal effects were observed at 0.29 ± 0.01 mm in cortical and 0.17 ± 0.02 mm in spinal cultures corresponding to 0.83 ± 0.03 MAC (1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects) and 0.49 ± 0.05 MAC, respectively. In contrast to sevoflurane, acetylcholine increased firing rates in both cortical (  C  ) and spinal slices (  D  ) up to twofold to threefold. Cholinergic enhancement of action potential activity was more pronounced in cortical compared with spinal slices. 
Fig. 2. Concentration-dependent effects of sevoflurane and acetylcholine in neocortical and spinal tissue slices. Levels of neuronal activity have been normalized to facilitate comparison. Sevoflurane reduced spontaneous activity of cortical (  A  ) and spinal neurons (  B  ) concentration-dependently within a range of clinically relevant concentrations. The anesthetic completely depressed neuronal activity at high concentrations in both preparations. Half-maximal effects were observed at 0.29 ± 0.01 mm in cortical and 0.17 ± 0.02 mm in spinal cultures corresponding to 0.83 ± 0.03 MAC (1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects) and 0.49 ± 0.05 MAC, respectively. In contrast to sevoflurane, acetylcholine increased firing rates in both cortical (  C  ) and spinal slices (  D  ) up to twofold to threefold. Cholinergic enhancement of action potential activity was more pronounced in cortical compared with spinal slices. 
Fig. 2. Concentration-dependent effects of sevoflurane and acetylcholine in neocortical and spinal tissue slices. Levels of neuronal activity have been normalized to facilitate comparison. Sevoflurane reduced spontaneous activity of cortical (  A  ) and spinal neurons (  B  ) concentration-dependently within a range of clinically relevant concentrations. The anesthetic completely depressed neuronal activity at high concentrations in both preparations. Half-maximal effects were observed at 0.29 ± 0.01 mm in cortical and 0.17 ± 0.02 mm in spinal cultures corresponding to 0.83 ± 0.03 MAC (1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects) and 0.49 ± 0.05 MAC, respectively. In contrast to sevoflurane, acetylcholine increased firing rates in both cortical (  C  ) and spinal slices (  D  ) up to twofold to threefold. Cholinergic enhancement of action potential activity was more pronounced in cortical compared with spinal slices. 
×
Fig. 3. Acetylcholine is released intrinsically in cortical and spinal tissue slices. The reversible acetylcholinesterase inhibitor neostigmine approximately doubled the firing rate at a concentration of 1 μm in cortical and spinal cultures, suggesting the existence of an intrinsic cholinergic release. This finding was corroborated by the observation that atropine, a competitive antagonist at muscarinic receptors, reduced action potential firing in both preparations by approximately 50%. 
Fig. 3. Acetylcholine is released intrinsically in cortical and spinal tissue slices. The reversible acetylcholinesterase inhibitor neostigmine approximately doubled the firing rate at a concentration of 1 μm in cortical and spinal cultures, suggesting the existence of an intrinsic cholinergic release. This finding was corroborated by the observation that atropine, a competitive antagonist at muscarinic receptors, reduced action potential firing in both preparations by approximately 50%. 
Fig. 3. Acetylcholine is released intrinsically in cortical and spinal tissue slices. The reversible acetylcholinesterase inhibitor neostigmine approximately doubled the firing rate at a concentration of 1 μm in cortical and spinal cultures, suggesting the existence of an intrinsic cholinergic release. This finding was corroborated by the observation that atropine, a competitive antagonist at muscarinic receptors, reduced action potential firing in both preparations by approximately 50%. 
×
Fig. 4. Cholinergic modulation of sevoflurane effects on network activity in cortical and spinal slices. (  A  ) Acetylcholine augmented neuronal firing rates in cortical slices at all sevoflurane concentrations tested, causing a concentration-dependent rightward and upward shift of the sevoflurane concentration–response curve. (  B  ) In spinal slices, 10 μm acetylcholine produced a less pronounced increase in action potential activity. (  C  ) Cholinergic modulation of normalized data of action potential activity depressed by sevoflurane in cortical slices. Acetylcholine increased the EC50from 0.83 ± 0.03 MAC (1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects) in the absence of acetylcholine to 1.59 ± 0.32 MAC (1 μm acetylcholine) and 2.68 ± 0.57 MAC (10 μm acetylcholine). The concentration–response curves of sevoflurane measured in the presence of acetylcholine differed significantly from the concentration–response curve in the absence of acetylcholine (  P  < 0.001, F test). (  D  ) Acetylcholine did not reduce the potency of sevoflurane in depressing spinal neurons (0.49 ± 0.05 MAC in the absence compared with 0.47 ± 0.10 MAC in the presence of acetylcholine). The concentration–response curves did not differ significantly (  P  > 0.1, F test). 
Fig. 4. Cholinergic modulation of sevoflurane effects on network activity in cortical and spinal slices. (  A  ) Acetylcholine augmented neuronal firing rates in cortical slices at all sevoflurane concentrations tested, causing a concentration-dependent rightward and upward shift of the sevoflurane concentration–response curve. (  B  ) In spinal slices, 10 μm acetylcholine produced a less pronounced increase in action potential activity. (  C  ) Cholinergic modulation of normalized data of action potential activity depressed by sevoflurane in cortical slices. Acetylcholine increased the EC50from 0.83 ± 0.03 MAC (1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects) in the absence of acetylcholine to 1.59 ± 0.32 MAC (1 μm acetylcholine) and 2.68 ± 0.57 MAC (10 μm acetylcholine). The concentration–response curves of sevoflurane measured in the presence of acetylcholine differed significantly from the concentration–response curve in the absence of acetylcholine (  P  < 0.001, F test). (  D  ) Acetylcholine did not reduce the potency of sevoflurane in depressing spinal neurons (0.49 ± 0.05 MAC in the absence compared with 0.47 ± 0.10 MAC in the presence of acetylcholine). The concentration–response curves did not differ significantly (  P  > 0.1, F test). 
Fig. 4. Cholinergic modulation of sevoflurane effects on network activity in cortical and spinal slices. (  A  ) Acetylcholine augmented neuronal firing rates in cortical slices at all sevoflurane concentrations tested, causing a concentration-dependent rightward and upward shift of the sevoflurane concentration–response curve. (  B  ) In spinal slices, 10 μm acetylcholine produced a less pronounced increase in action potential activity. (  C  ) Cholinergic modulation of normalized data of action potential activity depressed by sevoflurane in cortical slices. Acetylcholine increased the EC50from 0.83 ± 0.03 MAC (1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects) in the absence of acetylcholine to 1.59 ± 0.32 MAC (1 μm acetylcholine) and 2.68 ± 0.57 MAC (10 μm acetylcholine). The concentration–response curves of sevoflurane measured in the presence of acetylcholine differed significantly from the concentration–response curve in the absence of acetylcholine (  P  < 0.001, F test). (  D  ) Acetylcholine did not reduce the potency of sevoflurane in depressing spinal neurons (0.49 ± 0.05 MAC in the absence compared with 0.47 ± 0.10 MAC in the presence of acetylcholine). The concentration–response curves did not differ significantly (  P  > 0.1, F test). 
×
Fig. 5. Bicuculline effects on the potency of sevoflurane in depressing neuronal network activity in cortical and spinal slices. (  A  ) Action potential activity was approximately doubled by 1 μm bicuculline in both preparations in the absence of sevoflurane (*  P  < 0.05,  t  test, n = 10). (  B  ) In neocortical slices, 1 μm bicuculline induced an increase in EC50of sevoflurane from 0.83 ± 0.03 MAC (1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects) to 1.44 ± 0.26 MAC. Both concentration–response curves differed significantly (  P  < 0.01, F test). (  C  ) In contrast to neocortical slices, bicuculline did not affect the potency of sevoflurane in depressing spinal neurons (0.49 ± 0.05 MAC in the absence compared with 0.42 ± 0.05 MAC in the presence of bicuculline). In accord with the EC50values, the concentration–response curves were not different (  P  > 0.1, F test). 
Fig. 5. Bicuculline effects on the potency of sevoflurane in depressing neuronal network activity in cortical and spinal slices. (  A  ) Action potential activity was approximately doubled by 1 μm bicuculline in both preparations in the absence of sevoflurane (*  P  < 0.05,  t  test, n = 10). (  B  ) In neocortical slices, 1 μm bicuculline induced an increase in EC50of sevoflurane from 0.83 ± 0.03 MAC (1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects) to 1.44 ± 0.26 MAC. Both concentration–response curves differed significantly (  P  < 0.01, F test). (  C  ) In contrast to neocortical slices, bicuculline did not affect the potency of sevoflurane in depressing spinal neurons (0.49 ± 0.05 MAC in the absence compared with 0.42 ± 0.05 MAC in the presence of bicuculline). In accord with the EC50values, the concentration–response curves were not different (  P  > 0.1, F test). 
Fig. 5. Bicuculline effects on the potency of sevoflurane in depressing neuronal network activity in cortical and spinal slices. (  A  ) Action potential activity was approximately doubled by 1 μm bicuculline in both preparations in the absence of sevoflurane (*  P  < 0.05,  t  test, n = 10). (  B  ) In neocortical slices, 1 μm bicuculline induced an increase in EC50of sevoflurane from 0.83 ± 0.03 MAC (1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects) to 1.44 ± 0.26 MAC. Both concentration–response curves differed significantly (  P  < 0.01, F test). (  C  ) In contrast to neocortical slices, bicuculline did not affect the potency of sevoflurane in depressing spinal neurons (0.49 ± 0.05 MAC in the absence compared with 0.42 ± 0.05 MAC in the presence of bicuculline). In accord with the EC50values, the concentration–response curves were not different (  P  > 0.1, F test). 
×
Fig. 6. Effects of 0.75 MAC sevoflurane (1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects) in the absence and presence of 100 μm bicuculline. A concentration of 100 μm bicuculline abolished the depression of neuronal network activity by 0.26 mm (corresponding to 0.75 MAC) sevoflurane almost completely (from 49.61 ± 3.41% in the absence to 2.87 ± 5.13% in the presence of bicuculline; ***  P  < 0.001,  t  test, n = 10). This result points to enhanced synaptic inhibition mediated  via  γ-aminobutyric acid type A receptors being the predominate mechanism to cause the depressant effects of 0.75 MAC sevoflurane in neocortical slices. 
Fig. 6. Effects of 0.75 MAC sevoflurane (1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects) in the absence and presence of 100 μm bicuculline. A concentration of 100 μm bicuculline abolished the depression of neuronal network activity by 0.26 mm (corresponding to 0.75 MAC) sevoflurane almost completely (from 49.61 ± 3.41% in the absence to 2.87 ± 5.13% in the presence of bicuculline; ***  P  < 0.001,  t  test, n = 10). This result points to enhanced synaptic inhibition mediated  via  γ-aminobutyric acid type A receptors being the predominate mechanism to cause the depressant effects of 0.75 MAC sevoflurane in neocortical slices. 
Fig. 6. Effects of 0.75 MAC sevoflurane (1 MAC is defined to be the minimum alveolar concentration of an inhaled anesthetic required to suppress movement in response to noxious stimulation in 50% of subjects) in the absence and presence of 100 μm bicuculline. A concentration of 100 μm bicuculline abolished the depression of neuronal network activity by 0.26 mm (corresponding to 0.75 MAC) sevoflurane almost completely (from 49.61 ± 3.41% in the absence to 2.87 ± 5.13% in the presence of bicuculline; ***  P  < 0.001,  t  test, n = 10). This result points to enhanced synaptic inhibition mediated  via  γ-aminobutyric acid type A receptors being the predominate mechanism to cause the depressant effects of 0.75 MAC sevoflurane in neocortical slices. 
×
Table 1. Parameters of Sevoflurane Concentration–Response Curves Measured in the Absence and Presence of Acetylcholine in Cultured Cortical and Spinal Slices 
Image not available
Table 1. Parameters of Sevoflurane Concentration–Response Curves Measured in the Absence and Presence of Acetylcholine in Cultured Cortical and Spinal Slices 
×